FDA Approves First New Drug Under International Collaboration, A Treatment Option for Patients with HER2-Positive Metastatic Breast Cancer

FDA Approves First New Drug Under International Collaboration, A Treatment Option for Patients with HER2-Positive Metastatic Breast Cancer

A blockbuster breast cancer niche has Roche and Sanofi in the lead

A blockbuster breast cancer niche has Roche and Sanofi in the lead

SABCS: Pfizer’s Ibrance backs up benefit in HER2-negative breast cancer with real-world data

SABCS: Pfizer's Ibrance backs up benefit in HER2-negative breast cancer with real-world data

Roche’s Tecentriq and Companion Diagnostic Gets FDA Nod for Triple-Negative Breast Cancer

Roche's Tecentriq and Companion Diagnostic Gets FDA Nod for Triple-Negative Breast Cancer

Top 10 Immuno-Oncology Startups

Top 10 Immuno-Oncology Startups

US FDA Approves ONTRUZANT® (trastuzumab-dttb), Samsung Bioepis’ First Oncology Medicine in the United States

  Κάντε like στη σελίδα μας στο facebook για να μαθαίνετε πρώτοι όλα τα νέα!!    Samsung Bioepis Co., Ltd. today announced that the U.S.Food and Drug Administration (FDA) has approved ONTRUZANT® (trastuzumab-dttb), a biosimilar referencing HERCEPTIN® 1 (trastuzumab), across all eligible indications, namely adjuvant treatment of HER2-overexpressing breast cancer, metastatic breast cancer and metastatic gastric cancer or gastroesophageal junction adenocarcinoma … Συνεχίστε να διαβάζετε US FDA Approves ONTRUZANT® (trastuzumab-dttb), Samsung Bioepis’ First Oncology Medicine in the United States.